China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a multi-center, open Phase II study for its adebrelimab (SHR-1316) combined with other anti-tumor drugs in solid tumors. This approval paves the way for evaluating the efficacy and safety of adebrelimab in combination with several investigational novel cancer therapies.
Investigational Therapies
The trial will involve the following investigational drugs:
- SHR-8068: An in-licensed CTLA-4 monoclonal antibody (mAb).
- SHR-1826: A c-MET targeted antibody drug conjugate (ADC), with no similar products approved globally.
- SHR-A1904: A Claudin18.2-targeted ADC.
- SHR-A2009: An ADC targeting HER3, with no similar products approved globally.
- SHR-A2102: A Nectin-4-targeted ADC with topoisomerase inhibitor (TOPi) as payload.-Fineline Info & Tech
